The gap is narrowing as newer GLP-1 and multi-receptor agonist medications are developed
Ten GLP-1 drugs are FDA-approved to treat either type 2 diabetes or weight loss
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Semaglutide Peptide: Benefits, Uses, Side Effects, Dosage, and Research
However, as clinicians celebrate these advances, a Read More Beyond the FIB-4: Why Diabetes Care Is Becoming a Hepatology-Endocrinology Partnership May 20, 2026 Articles, Diabetes, Gastroenterology, Obesity, Obesity, Type 2 Diabetes, Type 2 Diabetes 1,761 views Screening for fatty liver disease in patients with diabetes is no longer limited to identifying elevated liver enzymes or calculating a fibrosis score during an annual visit
[DOI] [PubMed] [Google Scholar] 61.Sattar N, et al